$ 0.7
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
In Guru Portfolios
Data is available to registered users only
Data is available to registered users only
Portfolio Weight (%)
Data is available to registered users only
Change
Data is available to registered users only
Fund
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Portfolio Weight (%)
Data is available to registered users only
Change
Data is available to registered users only
Fund
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Portfolio Weight (%)
Data is available to registered users only
Change
Data is available to registered users only
Fund
Data is available to registered users only
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
About
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers.
Data is available to registered users only